Login to Your Account

GSK, ChemoCentryx Move to Phase III with Crohn's Drug

By Marie Powers

Thursday, January 13, 2011
Fewer than five years after inking a partnership deal focused on treatments for inflammatory disorders, privately held ChemoCentryx Inc., of Mountain View, Calif., and GlaxoSmithKline plc, of London, started treating the first patient with Crohn's disease in their initial induction study comparing Traficet-EN (CCX282-B) – now designated GSK1605786 ('786) – to placebo. The Phase III program is being conducted through GSK's Center of Excellence for External Drug Discovery (CEEDD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription